medcelerator · clinician one-pager

New Daily Pill to Lower High ("Bad") Cholesterol

Lipfendra (enlicitide) — first oral PCSK9 inhibitor for high LDL-C in adults

FDA Approved · United States · September 7, 2026

Condition: High LDL Cholesterol

Who this is for

Lipfendra (enlicitide) is a daily pill taken on an empty stomach. The United States approved it, with diet and exercise, to lower “bad” cholesterol in adults. It is not yet proven to prevent heart attacks or strokes.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220848Orig1s000lbl.pdf
United States · Recruiting clinical trial
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Combination or different setting. Children 6-17 with heterozygous FH; the article is adults (phase 2/3).
https://clinicaltrials.gov/study/NCT07058077

See 1 trial on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=hypercholesterolemia&intr=enlicitide&aggFilters=status:rec

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/lipfendra-enlicitide